التفاصيل البيبلوغرافية
| العنوان: |
Inadequate Use of Newer Treatments and Glycemic Control by Cardiovascular Risk and Sociodemographic Groups in US Adults with Diabetes in the NIH Precision Medicine Initiative All of Us Research Program. |
| المؤلفون: |
Devineni, Divya, Akbarpour, Meleeka, Gong, Yufan, Wong, Nathan |
| المصدر: |
Cardiovascular Drugs and Therapy, vol 38, iss 2 |
| بيانات النشر: |
eScholarship, University of California |
| سنة النشر: |
2024 |
| المجموعة: |
University of California: eScholarship |
| مصطلحات موضوعية: |
Cardiovascular risk, Diabetes, GLP-1 receptor agonists, SGLT2-inhibitors, Adult, Male, Humans, Glycemic Control, Precision Medicine, Cardiovascular Diseases, Sodium-Glucose Transporter 2, Risk Factors, Population Health, Diabetes Mellitus, Heart Disease Risk Factors, Atherosclerosis, Glucagon-Like Peptide 1, Glucose, Type 2, Glucagon-Like Peptide-1 Receptor, Hypoglycemic Agents |
| الوصف: |
PURPOSE: Data are limited on sodium glucose co-transport 2 inhibitors (SGLT2-is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among real-world cohorts of underrepresented patients. We examined these therapies and glycemic control in US adults with diabetes mellitus (DM) by atherosclerotic cardiovascular disease (ASCVD) risk and sociodemographic factors. METHODS: In the NIH Precision Medicine Initiative All of Us Research Program, we categorized DM as (1) moderate risk, (2) high risk, and (3) with ASCVD. We examined proportions on DM therapies, including SGLT2-i or GLP-1 RA, and at glycemic control by sociodemographic factors and CVD risk groups. RESULTS: Our 81,332 adults aged ≥ 18years with DM across 340 US sites included 22.3% non-Hispanic Black, 17.2% Hispanic, and 1.8% Asian participants; 31.1%, 30.3%, and 38.6% were at moderate risk, high risk, or with ASCVD, respectively. Those with DM and ASCVD were most likely on SGLT2-i (8.6%) or GLP-1 RA (11.9%). SGLT2-i use was < 10% in those with heart failure or chronic kidney disease. The odds (95% CI) of SGLT2-i use were greater among men (1.35 [1.20, 1.53]) and Asian persons (2.31 [1.78, 2.96]), with GLP-1 RA being less common (0.78 [0.70, 0.86]) in men. GLP-1 RA use was greater among those with health insurance, and both GLP-1 RA and SGLT2-i greater within lower income groups. 72.0% of participants had HbA1c < 7%; Hispanic persons were least likely at glycemic control. CONCLUSIONS: Treatment with SGLT2-is and GLP-1 RAs remains low, even among higher ASCVD risk persons with DM and use is even lower among underserved groups. |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
unknown |
| العلاقة: |
qt4qr8161g; https://escholarship.org/uc/item/4qr8161gTest |
| الإتاحة: |
https://escholarship.org/uc/item/4qr8161gTest |
| حقوق: |
public |
| رقم الانضمام: |
edsbas.C32F4AD9 |
| قاعدة البيانات: |
BASE |
